Characterising the risk of Hepatitis E virus infection in haematological malignancies: a UK prospective prevalence study

Br J Haematol. 2019 Jul;186(1):191-195. doi: 10.1111/bjh.15796. Epub 2019 Feb 15.

Michael J Ankcorn^{1

2}, Thomas A Fox³, Samreen Ijaz¹, Claire Nicholas³, Eric Houston³, Ian Longair³, Deepak Suri⁴, Frank M Mattes⁵, Jemma L Walker^{6

7}, Richard S Tedder^{1

2

8}, Mallika Sekhar^{3

9

10}

¹ Blood Borne Virus Unit, Virus Reference Department, National Infection Service, Public Health England, London, UK.
² Transfusion Microbiology, National Health Service Blood and Transplant, London, UK.
³ Department of Haematology, University College London Hospitals, London, UK.
⁴ Department of Hepatology, University College London Hospitals, London, UK.
⁵ Department of Virology, University College London Hospitals, London, UK.
⁶ Statistics and Modelling Economics Department, Public Health England, London, UK.
⁷ Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK.
⁸ Department of Medicine, Imperial College London, London, UK.
⁹ University College London, London, UK.
¹⁰ Royal Free London Hospital NHS Trust, London, UK.

No abstract available

Keywords: haematological malignancy; hepatitis E virus; immunocompromised; multiple myeloma; screening.

Publication types